港股创新药板块再度走强，恒生创新药ETF（159316）标的指数涨超3%

Core Viewpoint - The Hong Kong innovative drug sector continues to rise, with the Hang Seng Innovative Drug Index increasing by 3.2% shortly after market opening, driven by significant gains in constituent stocks such as InnoCare Pharma and 3SBio [1] Group 1: Market Performance - The Hang Seng Innovative Drug Index rose by 3.2% within the first half hour of trading [1] - InnoCare Pharma-B surged over 10%, while 3SBio increased by over 6%, and both CanSino Biologics and BGI Genomics rose by over 5% [1] Group 2: Upcoming Events - The 2025 European Society for Medical Oncology (ESMO) annual meeting is scheduled from October 17 to October 21 in Berlin, Germany, expected to be a significant platform for domestic pharmaceutical companies to showcase their achievements and facilitate new business development (BD) agreements [1] Group 3: Market Trends and Policies - October to November is traditionally a peak season for BD transactions, with notable deals already initiated by companies like Innovent Biologics, indicating potential for continued activity in the sector [1] - The adjustment window for the medical insurance catalog has opened, with clear policy support for genuine innovation, providing stable expectations for commercialization [1] - The Federal Reserve's potential interest rate cuts may benefit the innovative drug sector through improved valuation and financing conditions [1] Group 4: Index Composition and Investment Products - The Hang Seng Innovative Drug Index is the first "pure" innovative drug index with 100% purity, excluding CXO companies, allowing for an accurate reflection of the overall performance of China's innovative drug firms [1] - The Hang Seng Innovative Drug ETF (159316) is currently the only product tracking this index, having attracted over 500 million yuan in the last 10 trading days, facilitating investor access to leading innovative drug companies [1]